IQVIA brings together exceptional expertise in diabetes across the product lifecycle to help you increase the efficiency of your development program and maximize the value of new therapies.
In a recent Phase III Type I diabetes trial, IQVIA faced aggressive timelines to meet a submission deadline.
Through the power of the IQVIA CORE, we were able to accelerate both site ID and patient recruitment1 to help our customer meet the critical regulatory filing dates.
1 Comparison based on previous studies conducted by IQVIA in the same indication and geographies.
HbA1c measures alone are no longer enough in diabetes drug development. Continuous Glucose Monitoring (CGM) is increasingly becoming a part of clinical research as well as routine patient management, as it helps improve medication compliance and enforce lifestyle interventions and overall protocol adherence.
IQVIA’s CGM solution has been recognized as a valid research tool. It is one of the few CGM solutions that are compliant with 21 CFR Part 11. By integrating devices with our automated data capture and advanced analytics, we’re able to deliver more robust data, with less delay – so you can reach better decisions, faster.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Bring trials directly to patients to decrease costs, increase quality and improve access.
Use emerging data sources and advances in evidence methods to demonstrate product value and safety.